ESC Premium Access

Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial

Presentation

About the speaker

Professor Jochen Seufert

University of Freiburg, Freiburg (Germany)
0 follower

5 more presentations in this session

Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial

Speaker: Professor S. Verma (Toronto, CA)

Thumbnail

Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme

Speaker: Professor S. Bain (Swansea, GB)

Thumbnail

MRI evaluation of the impact of metformin and dapagloflizin on epicardial adipose tissue area in prediabetes and type 2 diabetes patients

Speaker: Professor C. Lang (Dundee, GB)

Thumbnail

A systematic review and meta-analysis of anti-cytokine therapies targeting IL-1 and TNF- A in myocardial infarction and heart failure

Speaker: Ms M. Panahi (London, GB)

Thumbnail

Additional therapy with nicorandil and quality of life in patients with stable coronary heart disease: a multicenter observational study

Speaker: Professor S. Martsevich (Moscow, RU)

Thumbnail

Access the full session

Poster Session 3 - Cardiac patients with comorbidities

Speakers: Professor J. Seufert, Professor S. Verma, Professor S. Bain, Professor C. Lang, Ms M. Panahi...
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk